Basics Coherus BioSciences, Inc. Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines. IPO Date: November 6, 2014 Sector: Healthcare Industry: Biotech Market Cap: $143.84M Activated in VL: True Average Daily Range Avg Daily Range: $0.38 | 3.09% Avg Daily Range (30 D): $0.05 | 3.48% Avg Daily Range (90 D): $0.05 | 3.71% Institutional Daily Volume Avg Daily Volume: 1.1M Avg Daily Volume (30 D): 1.15M Avg Daily Volume (90 D): 1.21M Trade Size Avg Trade Size (Sh.): 153 Avg Trade Size (Sh.) (30 D): 292 Avg Trade Size (Sh.) (90 D): 329 Institutional Trades Total Inst.Trades: 3,193 Avg Inst. Trade: $1.5M Avg Inst. Trade (30 D): $.61M Avg Inst. Trade (90 D): $.82M Avg Inst. Trade Volume: .13M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.76M Avg Closing Trade (30 D): $.61M Avg Closing Trade (90 D): $.61M Avg Closing Volume: 158.69K     News Nov 6, 2025 @ 6:54 PM Arvind Sood joins Coherus Oncology as Chief Strate... Source: Denny Lanfear Apr 1, 2025 @ 12:00 PM Coherus Announces Repurchase of Approximately $170... Source: Coherus Biosciences, Inc. Jul 30, 2024 @ 5:00 PM Hepatic Tumor Clinical Trial Pipeline Experiences ... Source: Delveinsight Jun 27, 2024 @ 12:26 PM Coherus BioSciences Announces Divestiture of YUSIM... Source: Coherus BioSciences, Inc. Jun 23, 2024 @ 3:13 PM Pfizer: Seriously Undervalued At Peak Pessimism Source: ALLKA Research Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.31 $2.57 $-.49 Diluted EPS $-.31 $2.57 $-.49 Revenue $ 11.57M $ 10.25M $ 7.6M Gross Profit $ 7.85M $ 6.86M $ 4.95M Net Income / Loss $ -35.53M $ 297.77M $ -56.57M Operating Income / Loss $ -44.33M $ -45.49M $ -45.44M Cost of Revenue $ 3.72M $ 3.4M $ 2.65M Net Cash Flow $ -113.56M $ 134.48M $ -43.58M PE Ratio